Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
ID: 348234Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348234

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html
Timeline
    Description

    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has announced a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to facilitate the development of non-hormonal contraceptives and reproductive health products by providing access to essential preclinical services, including protein generation, high throughput screening, and drug metabolism studies, rather than direct funding. The program is particularly significant in addressing the urgent need for effective contraceptive methods and advancing innovative research in reproductive health. Interested applicants, including various educational and community organizations, must adhere to specific guidelines and submit their applications by April 3, 2026, with an initial deadline of October 3, 2023. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-193-Full-Announcement.html
    PAR-23-193.html
    The Department of Health and Human Services, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has released a funding opportunity aimed at facilitating the development of non-hormonal contraceptives and reproductive health products via its Chemical Screening and Optimization Facility (CSOF). This initiative, designated as the X01 Resource Access Award, does not provide direct funding but offers access to various preclinical services essential for research, including protein generation, high throughput screening, and drug metabolism studies. Key details include application deadlines of October 3, 2023, and repeated cycles until 2026. The goal is to enable the advancement of projects that show promise in reproductive health, thereby addressing the urgent need for effective contraceptive methods. Applicants are encouraged to reach out to NICHD staff for guidance prior to submission. The application process requires adherence to specific guidelines, with an emphasis on target validation and the expected impacts on product development. Researchers must demonstrate compliance with NIH policy and clear project advancement plans. Overall, this funding opportunity aims to push forward innovative research while ensuring strong support for public health initiatives related to reproductive health.
    Similar Opportunities
    Biological Testing Facility for Contraception & Reproductive Health
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for access to a state-of-the-art Biological Testing Facility (BTF) aimed at advancing contraceptive and reproductive health-related product development. This initiative seeks to support innovative and validated methods for fertility regulation and the development of new therapies in reproductive health, addressing a critical need for effective fertility regulation methods. While applications are not currently being solicited, potential applicants are encouraged to prepare their projects in anticipation of the opportunity, with an estimated synopsis post date of October 6, 2025, and an estimated award date of February 23, 2026. For further inquiries, interested parties can contact Dr. Leigh Allen at leigh.allen@nih.gov or by phone at 301-594-9151.
    Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the development of novel or improved infertility technologies through a phased R61/R33 grant mechanism. This initiative aims to support multidisciplinary research focused on creating or enhancing technologies, including drugs, devices, and clinical practices, to improve fertility outcomes, particularly in the context of assisted reproductive technologies (ART). With an estimated total program funding of $3.3 million and the expectation of awarding 11 grants, potential applicants are encouraged to prepare collaborative projects in advance of the official solicitation, which is anticipated to be published in July 2025. For further inquiries, interested parties can contact Travis Kent, PhD, at travis.kent@mail.nih.gov or call 301-435-2295.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials aligned with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This program aims to fund small-scale research projects, including pilot studies and methodological development, with a maximum budget of $50,000 per year for up to two years. The funding is crucial for advancing knowledge in human development fields, particularly in childhood development and rehabilitation medicine. Interested applicants must adhere to specific guidelines and register with Grants.gov and eRA Commons, with the application window opening on January 16, 2025, and closing on January 8, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which provides funding for basic experimental studies involving human participants that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant supports clinical trials aimed at understanding fundamental aspects of phenomena without immediate application to processes or products, encouraging innovative research in areas such as contraception and childhood development. Eligible applicants include a wide range of entities, such as higher education institutions, nonprofits, and tribal organizations, with a funding ceiling of $50,000 available over a maximum of two years. Interested parties should note that the application period opens on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.